Literature DB >> 27632388

Interplay of nuclear receptors (ER, PR, and GR) and their steroid hormones in MCF-7 cells.

Shubha M Hegde1, M Naveen Kumar1, K Kavya1, K M Kiran Kumar1, Rashmi Nagesh1, Rajeshwari H Patil1, R L Babu2, Govindarajan T Ramesh3, S Chidananda Sharma4.   

Abstract

Steroid hormones and their nuclear receptors play a major role in the development and progression of breast cancer. MCF-7 cells are triple-positive breast cancer cells expressing estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). However, interaction and their role in expression pattern of activator protein (AP-1) transcription factors (TFs) are not completely understood. Hence, in our study, MCF-7 cells were used as an in vitro model system to study the interplay between the receptors and hormones. MCF-7 cells were treated with estradiol-17β (E2), progesterone (P4), and dexamethasone (Dex), alone or in combination, to study the proliferation of cells and expression of AP-1 genes. MTT assay results show that E2 or P4 induced the cell proliferation by more than 35 %, and Dex decreased the proliferation by 26 %. E2 and P4 are found to increase ERα by more than twofold and c-Jun, c-Fos, and Fra-1 AP-1 TFs by more than 1.7-fold, while Dex shows opposite effect of E2- or P4-induced effect as well as effect on the expression of nuclear receptors and AP-1 factors. E2 antagonist Fulvestrant (ICI 182,780) found to reduce proliferation and E2-induced expression of AP1-TFs, while P4 or Dex antagonist Mifepristone (RU486) is found to block GR-mediated expression of NRs and AP-1 mRNAs. Results suggest that E2 and P4 act synergistically, and Dex acts as an antagonist of E2 and P4.

Entities:  

Keywords:  AP-1; MCF-7; Nuclear receptors; RT-PCR; Steroid hormones

Mesh:

Substances:

Year:  2016        PMID: 27632388     DOI: 10.1007/s11010-016-2810-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

Review 1.  Progestin regulation of cellular proliferation.

Authors:  C L Clarke; R L Sutherland
Journal:  Endocr Rev       Date:  1990-05       Impact factor: 19.871

2.  Role of oestradiol-17 beta in the regulation of synthesis and secretion of human chorionic gonadotrophin by first trimester human placenta.

Authors:  S C Sharma; P Purohit; A J Rao
Journal:  J Mol Endocrinol       Date:  1993-08       Impact factor: 5.098

3.  Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.

Authors:  Deng Pan; Masha Kocherginsky; Suzanne D Conzen
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

Review 4.  Non-genomic actions of sex steroid hormones.

Authors:  Tommaso Simoncini; Andrea R Genazzani
Journal:  Eur J Endocrinol       Date:  2003-03       Impact factor: 6.664

Review 5.  Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

Authors:  Xiaojiang Cui; Rachel Schiff; Grazia Arpino; C Kent Osborne; Adrian V Lee
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

6.  Glucocorticoids augment survival and proliferation of tumor cells.

Authors:  Sibylle Gündisch; Eva Boeckeler; Uta Behrends; Eberhard Amtmann; Harald Ehrhardt; Irmela Jeremias
Journal:  Anticancer Res       Date:  2012-10       Impact factor: 2.480

7.  Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells.

Authors:  Joyce C L Leo; Chunhua Guo; Chow Thai Woon; Swee Eng Aw; Valerie C L Lin
Journal:  Endocrinology       Date:  2003-11-14       Impact factor: 4.736

8.  Antiproliferative effect of dexamethasone in the MCF-7 breast cancer cell line.

Authors:  Frederic Buxant; Nadège Kindt; Guy Laurent; Jean-Christophe Noël; Sven Saussez
Journal:  Mol Med Rep       Date:  2015-06-12       Impact factor: 2.952

9.  Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses.

Authors:  Michael J Bolt; Fabio Stossi; Justin Y Newberg; Arturo Orjalo; Hans E Johansson; Michael A Mancini
Journal:  Nucleic Acids Res       Date:  2013-02-26       Impact factor: 16.971

10.  Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.

Authors:  A R Daniel; A L Gaviglio; T P Knutson; J H Ostrander; A B D'Assoro; P Ravindranathan; Y Peng; G V Raj; D Yee; C A Lange
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

View more
  10 in total

1.  Progesterone and estrogen regulate NALCN expression in human myometrial smooth muscle cells.

Authors:  Chinwendu Amazu; Xiaofeng Ma; Clara Henkes; Juan J Ferreira; Celia M Santi; Sarah K England
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-01-14       Impact factor: 4.310

2.  Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status.

Authors:  K Kavya; M Naveen Kumar; Rajeshwari H Patil; Shubha M Hegde; K M Kiran Kumar; Rashmi Nagesh; R L Babu; Govindarajan T Ramesh; S Chidananda Sharma
Journal:  Mol Cell Biochem       Date:  2017-04-06       Impact factor: 3.396

Review 3.  Chromatin reprogramming in breast cancer.

Authors:  Erin E Swinstead; Ville Paakinaho; Gordon L Hager
Journal:  Endocr Relat Cancer       Date:  2018-04-24       Impact factor: 5.678

Review 4.  Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers.

Authors:  Thu H Truong; Carol A Lange
Journal:  Endocrinology       Date:  2018-12-01       Impact factor: 4.736

5.  Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas.

Authors:  Yu-Jie Dai; Yi-Bo Qiu; Rong Jiang; Man Xu; Le Zhao; George G Chen; Zhi-Min Liu
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

Review 6.  The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression.

Authors:  Hiroki Ide; Satoshi Inoue; Hiroshi Miyamoto
Journal:  Cancers (Basel)       Date:  2018-12-04       Impact factor: 6.639

7.  The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.

Authors:  Maria F Ogara; Santiago A Rodríguez-Seguí; Melisa Marini; Ana Silvina Nacht; Martin Stortz; Valeria Levi; Diego M Presman; Guillermo P Vicent; Adali Pecci
Journal:  Nucleic Acids Res       Date:  2019-11-18       Impact factor: 16.971

8.  PGRMC1 Inhibits Progesterone-Evoked Proliferation and Ca2+ Entry Via STIM2 in MDA-MB-231 Cells.

Authors:  Carlos Cantonero; Ginés M Salido; Juan A Rosado; Pedro C Redondo
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

Review 9.  Predisposition of Women to Cardiovascular Diseases: A Side-Effect of Increased Glucocorticoid Signaling During the COVID-19 Pandemic?

Authors:  Hemangini A Dhaibar; Diana Cruz-Topete
Journal:  Front Glob Womens Health       Date:  2021-02-16

10.  Breast Cancer Awareness and Barriers to Early Presentation in the Gaza-Strip: A Cross-Sectional Study.

Authors:  Mohamedraed Elshami; Hanan Abu Kmeil; Maymona Abu-Jazar; Ibtisam Mahfouz; Dina Ashour; Ansam Aljamal; Nada Mohareb; Reem Elbalaawi; Reem Dabbour; Jomana Ghaith; Tayseer Hasan; Meral Abdelati; Esraa Saleh; Haifa Shawwa; Reem Al-Ghazali; Ola Obaid; Loai Albarqouni; Bettina Böttcher
Journal:  J Glob Oncol       Date:  2018-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.